Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy

Blood Cancer J. 2015 Feb 6;5(2):e278. doi: 10.1038/bcj.2014.95.

Authors

Z R Chalmers¹, S M Ali¹, R S Ohgami², P V Campregher³, G M Frampton¹, R Yelensky¹, J A Elvin¹, N A Palma¹, R Erlich¹, J-A Vergilio⁴, J Chmielecki¹, J S Ross⁵, P J Stephens¹, R Hermann⁶, V A Miller¹, C R Miles⁶

Affiliations

¹ Foundation Medicine Inc., Cambridge, MA, USA.
² Department of Pathology, Stanford School of Medicine, Stanford, CA, USA.
³ 1] Foundation Medicine Inc., Cambridge, MA, USA [2] Clinical Laboratory, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
⁴ Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
⁵ 1] Foundation Medicine Inc., Cambridge, MA, USA [2] Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, USA.
⁶ Northwest Georgia Oncology Centers, Jasper Cancer Center, Jasper, GA, USA.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Benzamides / administration & dosage
Eosinophilia / drug therapy
Eosinophilia / genetics
Eosinophilia / pathology
Female
Genome, Human
High-Throughput Nucleotide Sequencing
Humans
Hypereosinophilic Syndrome / drug therapy
Hypereosinophilic Syndrome / genetics*
Hypereosinophilic Syndrome / pathology
Imatinib Mesylate
Leukemia
Middle Aged
Myeloproliferative Disorders
Oncogene Proteins, Fusion / genetics*
Oncogene Proteins, Fusion / isolation & purification
Piperazines / administration & dosage
Pyrimidines / administration & dosage
Receptor, Platelet-Derived Growth Factor alpha / genetics*
Tankyrases / genetics*

Substances

Benzamides
Oncogene Proteins, Fusion
Piperazines
Pyrimidines
Imatinib Mesylate
TNKS2 protein, human
Tankyrases
Receptor, Platelet-Derived Growth Factor alpha

Supplementary concepts

Pdgfra-Associated Chronic Eosinophilic Leukemia